- BY DIRECT INTRACAVERNOSAL INJECTION, ADULT OVER 18 YEARS, ERECTILE DYSFUNCTION, FIRST DOSE 2.5 MICROGRAMS, SECOND DOSE 5 MICROGRAMS (IF SOME RESPONSE TO FIRST DOSE) OR 7.5 MICROGRAMS (IF NO RESPONSE TO FIRST DOSE), INCREASING IN STEPS OF 5-10 MICROGRAMS TO OBTAIN DOSE SUITABLE FOR PRODUCING ERECTION LASTING NOT MORE THAN 1 HOUR
- NEUROLOGICAL DYSFUNCTION, FIRST DOSE 1.25 MICROGRAMS, SECOND DOSE 2.5 MICROGRAMS, THIRD DOSE 5 MICROGRAMS, INCREASING IN STEPS OF 5-10 MICROGRAMS TO OBTAIN SUITABLE DOSE); IF NO RESPONSE TO DOSE THEN NEXT HIGHER DOSE CAN BE GIVEN WITHIN 1 HOUR, IF THERE IS A RESPONSE THE NEXT DOSE SHOULD NOT BE GIVEN FOR AT LEAST 24 HOURS; USUAL DOSE 5-20 MICROGRAMS; MAX. 60 MICROGRAMS; MAX. FREQUENCY OF INJECTION NOT MORE THAN 3 TIMES PER WEEK WITH AT LEAST 24 HOUR INTERVAL BETWEEN INJECTIONS.
PROSTIN VR PEDIATRIC STERILE SOLUTION IS INDICATED FOR PALLIATIVE, NOT DEFINITIVE, THERAPY TO TEMPORARILY MAINTAIN THE PATENCY OF THE DUCTUS ARTERIOSUS UNTIL CORRECTIVE OR PALLIATIVE SURGERY CAN BE PERFORMED IN NEONATES WHO HAVE CONGENITAL HEART DEFECTS AND WHO DEPEND UPON THE PATENT DUCTUS FOR SURVIVAL. SUCH CONGENITAL HEART DEFECTS INCLUDE
PULMONARY ATRESIA, PULMONARY STENOSIS, TRICUSPID ATRESIA, TETRALOGY OF FALLOT, INTERRUPTION OF THE AORTIC ARCH, COARCTATION OF THE AORTA, OR TRANSPOSITION OF THE GREAT VESSELS WITH OR WITHOUT OTHER DEFECTS.
- PATENT DUCTUS ARTERIOSUS - CONTINUOUS INFUSION INTO A LARGE VEIN OR THROUGH AN UMBLICAL ARTRY 0.05-0.1 MCG/KG/MT. TO TEMPORARILY MAINTAIN THE PATENCY OF DUCTUS ARTERIOSUS
IV SOLU - BY INTRAVENOUS INFUSION, INITIALLY 10 NANOGRAMS/KG/MINUTE, ADJUSTED ACCORDING TO RESPONSE IN STEPS OF 5-10 NANOGRAMS/KG/MINUTE; MAX. 100 NANOGRAMS/KG/MINUTE (BUT ASSOCIATED WITH INCREASED SIDE-EFFECTS).